Table 1 Patient characteristics (n = 72) and brain metastasis characteristics (n = 111)
From: Stereotactic radiosurgery of brain metastases: a retrospective study
Characteristics | Value |
|---|---|
Patient characteristics (n = 72) | |
Patient age, years, median (interquartile range, IQR) | 62 (55–68) |
Sex, n (%) | |
Men | 41 (56.9%) |
Women | 31 (43.1%) |
Primary cancer, n (%) | |
Malignant melanoma | 30 (41.7%) |
NSCLC adenocarcinoma | 21 (29.2%) |
NSCLC non-adenocarcinoma | 10 (13.9%) |
Breast cancer | 4 (5.6%) |
Gastrointestinal carcinoma | 3 (4.2%) |
Sarcoma | 2 (2.8%) |
Renal cell carcinoma | 1 (1.4%) |
Adrenal gland cancer | 1 (1.4%) |
Initial UICC stage, n (%) | |
I | 3 (4.2%) |
II | 10 (13.9%) |
III | 12 (16.7%) |
IV | 47 (65.3%) |
Karnofsky performance score, median (IQR) | 70 (70–80) |
Systemic treatment (chemotherapy, immunotherapy, targeted therapy, or anti-hormonal therapy) three months before/after SRS, n (%) | 65 (90.3%) |
Number of brain metastases treated with 18 Gy SRS, median (IQR) | 1.0 (1.0–2.0) |
Recursive partitioning analysis (RPA), median (IQR) | 2.0 (2.0–3.0) |
Diagnosis-specific graded prognostic assessment (ds-GPA), median (IQR) | 2.0 (1.5–3.0) |
Disease control of the primary cancer, n (%) | |
Yes | 42 (58.3%) |
No | 30 (41.7%) |
Extracranial metastases, n (%) | |
Yes | 43 (59.7%) |
No | 29 (40.3%) |
Brain metastasis characteristics (n = 111) | |
Cancer types | |
Malignant melanoma | 44 (39.6%) |
NSCLC adenocarcinoma | 28 (25.2%) |
NSCLC non-adenocarcinoma | 14 (12.6%) |
Breast cancer | 8 (7.2%) |
Gastrointestinal carcinoma | 8 (7.2%) |
Sarcoma | 6 (5.4%) |
Adrenal gland cancer | 2 (1.8%) |
Renal cell carcinoma | 1 (0.9%) |
Location, n (%) | |
Supratentorial | 97 (87.4%) |
Infratentorial | 14 (12.6%) |
Gross tumor volume, GTV (cm³) | |
Mean (Standard deviation, SD) | 0.50 (0.51) |
Median (IQR) | 0.30 (0.17–0.61) |
Planning target volume, PTV (cm³) | |
Mean (SD) | 1.91 (1.24) |
Median (IQR) | 1.57 (0.95–2.44) |
Response of metastases on 1st follow-up MRI after a median time of 47 days (IQR, 40–63), n (%) | |
Responsive disease † | 46 (41.4%) |
Stable disease ‡ | 59 (53.2%) |
Progressive disease § | 6 (5.4%) |